News
The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...
The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...
The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.
Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...
The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...
The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...
A second chikungunya vaccine may soon be available for travelers, officials say TUESDAY, May 13, 2025 (HealthDay News) — U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results